Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1996 Aug;118(8):1925–1930. doi: 10.1111/j.1476-5381.1996.tb15626.x

The role of endogenous bradykinin in blood pressure homeostasis in spontaneously hypertensive rats.

H R Holte 1, A Bjørnstad-Ostensen 1, T Berg 1
PMCID: PMC1909879  PMID: 8864525

Abstract

1. The role of endogenous bradykinin in mean arterial blood pressure (BP) homeostasis was studied in spontaneously hypertensive (SHR) and normotensive (WKY) rats by the use of a bradykinin B2-receptor antagonist (BKant; Hoe 140, 11.6 micrograms kg-1) and converting enzyme (kininase II) inhibitor (captopril, 10 mg). To obtain a response to captopril that was induced through inhibition of kinin-degradation only and not through inhibition of angiotensin II-formation, the studies were performed on binephrectomized male rats to eliminate the renin-angiotensin system. 2. The role of the nitric oxide (NO) and the adrenergic systems were evaluated by the use of NO-synthase inhibitor (L-NAME, 0.3 g kg-1) and phentolamine (2 mg kg-1), respectively. 3. The rats were anaesthetized and pretreated with two injections of vehicle (PBS) or drugs spaced 5 min apart: PBS + PBS; BKant + PBS; PBS + L-NAME; BKant + L-NAME; or phentolamine + L-NAME. All rats were given captopril 15 min later. Time-control groups were treated with L-NAME but not captopril. 4. In WKY rats, captopril did not significantly alter BP in any of the groups. In the SHR-PBS + PBS group, on the other hand, captopril induced an immediate fall in BP (delta BP = -23 +/- 4 mmHg, P < 0.0017) which was completely blocked by BKant (delta BP = 2 +/- 2 mmHg) (P < 0.0011). L-NAME did not significantly alter the immediate hypotensive response to captopril but disclosed a later hypertensive reaction. In L-NAME + BKant-treated rats, both the hypotensive response and the late hypertension was abolished. In rats treated with phentolamine + L-NAME, the immediate fall in BP was not different from the controls whereas the late hypertension was absent. 5. BKant itself had no effect on basal BP in either WKY or SHR even when a 10 times higher dose was tested in a separate set of experiments. This was true also for conscious, nonnephrectomized SHR rats. 6. It was concluded that endogenous production of bradykinin was demonstrable through kininase II-inhibition in hypertensive but not in normotensive rats. However, this endogenous bradykinin did not play a role in basal BP homeostasis. The captopril-induced hypotension depended on kinin but, under the present conditions, not on NO as a mediator. The fall in BP induced a compensatory adrenergic hypertensive response which was revealed when the continuous NO-synthesis was blocked by L-NAME.

Full text

PDF
1925

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Benetos A., Gavras H., Stewart J. M., Vavrek R. J., Hatinoglou S., Gavras I. Vasodepressor role of endogenous bradykinin assessed by a bradykinin antagonist. Hypertension. 1986 Nov;8(11):971–974. doi: 10.1161/01.hyp.8.11.971. [DOI] [PubMed] [Google Scholar]
  2. Benetos A., Gavras I., Gavras H. Hypertensive effect of a bradykinin antagonist in normotensive rats. Hypertension. 1986 Nov;8(11):1089–1092. doi: 10.1161/01.hyp.8.11.1089. [DOI] [PubMed] [Google Scholar]
  3. Berg T., Johansen L., Nustad K. Enzymatic activity of rat submandibular gland kallikrein released into blood. Am J Physiol. 1985 Dec;249(6 Pt 2):H1134–H1142. doi: 10.1152/ajpheart.1985.249.6.H1134. [DOI] [PubMed] [Google Scholar]
  4. Bjørnstad-Ostensen A., Berg T. The role of nitric oxide, adrenergic activation and kinin-degradation in blood pressure homeostasis following an acute kinin-induced hypotension. Br J Pharmacol. 1994 Dec;113(4):1567–1573. doi: 10.1111/j.1476-5381.1994.tb17175.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Cachofeiro V., Sakakibara T., Nasjletti A. Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension. Hypertension. 1992 Feb;19(2):138–145. doi: 10.1161/01.hyp.19.2.138. [DOI] [PubMed] [Google Scholar]
  6. Carbonell L. F., Carretero O. A., Stewart J. M., Scicli A. G. Effect of a kinin antagonist on the acute antihypertensive activity of enalaprilat in severe hypertension. Hypertension. 1988 Mar;11(3):239–243. doi: 10.1161/01.hyp.11.3.239. [DOI] [PubMed] [Google Scholar]
  7. Carretero O. A., Miyazaki S., Scicli A. G. Role of kinins in the acute antihypertensive effect of the converting enzyme inhibitor, captopril. Hypertension. 1981 Jan-Feb;3(1):18–22. doi: 10.1161/01.hyp.3.1.18. [DOI] [PubMed] [Google Scholar]
  8. Dzau V. J. Multiple pathways of angiotensin production in the blood vessel wall: evidence, possibilities and hypotheses. J Hypertens. 1989 Dec;7(12):933–936. doi: 10.1097/00004872-198912000-00001. [DOI] [PubMed] [Google Scholar]
  9. Gavras H., Brunner H. R., Turini G. A., Kershaw G. R., Tifft C. P., Cuttelod S., Gavras I., Vukovich R. A., McKinstry D. N. Antihypertensive effect of the oral angiotensin converting-enzyme inhibitor SQ 14225 in man. N Engl J Med. 1978 May 4;298(18):991–995. doi: 10.1056/NEJM197805042981803. [DOI] [PubMed] [Google Scholar]
  10. Inagami T., Murakami T., Higuchi K., Nakajo S. Roles of renal and vascular renin in spontaneous hypertension and switching of the mechanism upon nephrectomy. Lack of hypotensive effects of inhibition of renin, converting enzyme, and angiotensin II receptor blocker after bilateral nephrectomy. Am J Hypertens. 1991 Jan;4(1 Pt 2):15S–22S. doi: 10.1093/ajh/4.1.15s. [DOI] [PubMed] [Google Scholar]
  11. Kelm M., Schrader J. Nitric oxide release from the isolated guinea pig heart. Eur J Pharmacol. 1988 Oct 18;155(3):317–321. doi: 10.1016/0014-2999(88)90522-5. [DOI] [PubMed] [Google Scholar]
  12. Kiowski W., Linder L., Kleinbloesem C., van Brummelen P., Bühler F. R. Blood pressure control by the renin-angiotensin system in normotensive subjects. Assessment by angiotensin converting enzyme and renin inhibition. Circulation. 1992 Jan;85(1):1–8. doi: 10.1161/01.cir.85.1.1. [DOI] [PubMed] [Google Scholar]
  13. Mombouli J. V., Vanhoutte P. M. Endothelium-derived hyperpolarizing factor(s) and the potentiation of kinins by converting enzyme inhibitors. Am J Hypertens. 1995 May;8(5 Pt 2):19S–27S. doi: 10.1016/0895-7061(95)00029-o. [DOI] [PubMed] [Google Scholar]
  14. O'Shaughnessy K. M., Newman C. M., Warren J. B. Inhibition in the rat of nitric oxide synthesis in vivo does not attenuate the hypotensive action of acetylcholine, ATP or bradykinin. Exp Physiol. 1992 Mar;77(2):285–292. doi: 10.1113/expphysiol.1992.sp003588. [DOI] [PubMed] [Google Scholar]
  15. Orstavik T. B., Gautvik K. M. Regulation of salivary kallikrein secretion in submandibular gland. Acta Physiol Scand. 1977 May;100(1):33–44. doi: 10.1111/j.1748-1716.1977.tb05919.x. [DOI] [PubMed] [Google Scholar]
  16. Rees D. D., Palmer R. M., Schulz R., Hodson H. F., Moncada S. Characterization of three inhibitors of endothelial nitric oxide synthase in vitro and in vivo. Br J Pharmacol. 1990 Nov;101(3):746–752. doi: 10.1111/j.1476-5381.1990.tb14151.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Saed G. M., Carretero O. A., MacDonald R. J., Scicli A. G. Kallikrein messenger RNA in rat arteries and veins. Circ Res. 1990 Aug;67(2):510–516. doi: 10.1161/01.res.67.2.510. [DOI] [PubMed] [Google Scholar]
  18. Whittle B. J., Lopez-Belmonte J., Rees D. D. Modulation of the vasodepressor actions of acetylcholine, bradykinin, substance P and endothelin in the rat by a specific inhibitor of nitric oxide formation. Br J Pharmacol. 1989 Oct;98(2):646–652. doi: 10.1111/j.1476-5381.1989.tb12639.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Wirth K., Hock F. J., Albus U., Linz W., Alpermann H. G., Anagnostopoulos H., Henk S., Breipohl G., König W., Knolle J. Hoe 140 a new potent and long acting bradykinin-antagonist: in vivo studies. Br J Pharmacol. 1991 Mar;102(3):774–777. doi: 10.1111/j.1476-5381.1991.tb12249.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Yang H. Y., Erdös E. G., Levin Y. A dipeptidyl carboxypeptidase that converts angiotensin I and inactivates bradykinin. Biochim Biophys Acta. 1970 Aug 21;214(2):374–376. doi: 10.1016/0005-2795(70)90017-6. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES